Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial

Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial - Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total hip arthroplasty: randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029797

Enrollment

Registered

2017-11-02

Start date

2017-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the hip, Avascular necrosis of the femoral head, Rheumatoid arthritis

Interventions

The combined tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first hip. After closure of fascia, 1000 mg of tranexamic acid (10 mL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing simultaneous bilateral total hip arthroplasty

Exclusion criteria

Exclusion criteria: Known allergic reaction to tranexamic acid Refusal of blood products

Design outcomes

Primary

Measure	Time frame
The volume of perioperative blood loss measured using the calculated blood volume and change in hemoglobin from preoperative to postoperative day 4.	—

Secondary

Measure	Time frame
Complication	—

Countries

Japan

Contacts

Public ContactKenji Kurosaka

Hokusuikai Kinen Hospital Orthopaedic surgery

kenjikurosaka@yahoo.co.jp029-303-3003

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026